

# Media Release

## **Clariant signs an agreement regarding the sale of its Healthcare Packaging Business**

- **Divestment of Clariant's Healthcare Packaging Business to Arsenal Capital Partners**
- **Total consideration of approx. CHF 308 million**

Muttenz, July 22, 2019 - Clariant, a focused and innovative specialty chemical company, has signed an agreement with respect to the sale of its Healthcare Packaging business to a newly-formed affiliate of Arsenal Capital Partners. The total consideration of the sale amounts to approximately CHF 308 million payable at closing, which is expected in Q4 2019. The total consideration is equivalent to 13.2 times adjusted FY2018 EBITDA. The closing of the transaction is subject to customary conditions and approvals.

Clariant's Healthcare Packaging business offers products used to protect pharmaceutical products from moisture and oxygen. This includes customizable, high-quality drop-in products (canisters and packets), Integrated Desiccant Systems and specially designed plastic bottles containing oxygen barrier materials. In 2018, the Healthcare Packaging business generated sales of around CHF 135 million. The business has manufacturing facilities in the USA, France, China and India and employs around 600 employees.

**CORPORATE MEDIA RELATIONS**

**JOCHEN DUBIEL**

Phone +41 61 469 63 63  
jochen.dubiel@clariant.com

**CLAUDIA KAMENSKY**

Phone +41 61 469 63 63  
claudia.kamensky@clariant.com

**THIJS BOUWENS**

Phone +41 61 469 63 63  
Thijs.bouwens@clariant.com

**INVESTOR RELATIONS**

**ANJA POMREHN**

Phone +41 61 469 67 45  
anja.pomrehn@clariant.com

**MARIA IVEK**

Phone +41 61 469 63 73  
maria.ivek@clariant.com

Follow us on [Twitter](#), [Facebook](#), [Google Plus](#), [LinkedIn](#).

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

[www.clariant.com](http://www.clariant.com)

Clariant is a focused and innovative specialty chemical company, based in Muttenz near Basel/Switzerland. On 31 December 2018 the company employed a total workforce of 17 901. In the financial year 2018, Clariant recorded sales of CHF 6.623 billion for its continuing businesses. The company reports in four business areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings. Clariant's corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.